Company Overview of Otsuka Pharmaceutical Co., Ltd.
Otsuka Pharmaceutical Co., Ltd. engages in the development, production, distribution, export, and import of drugs for tuberculosis, rehydration, and central nervous system. It offers nutraceuticals, cosmedics, clinical testing equipment, medical device and equipment, medical food products, nutritional drinks, cosmetics, OTC drugs, and other related products. The company was founded in 1964 and is based in Tokyo, Japan with branch and district offices in Japan. It has operations in Asia, Europe, North America, and internationally. Otsuka Pharmaceutical Co., Ltd. operates as a subsidiary of Otsuka Holdings Co., Ltd.
2-9 Kanda Tsukasa-machi
Founded in 1964
Key Executives for Otsuka Pharmaceutical Co., Ltd.
President and Executive Director
Managing Director of Accounting, Finance & Business Promotion
Chairman of Otsuka Pharmaceutical Development & Commercialization Inc and Chief Executive Officer of Otsuka Pharmaceutical Development & Commercialization Inc
Senior Managing Director, General Manager of Production Headquarters and Director
Compensation as of Fiscal Year 2015.
Otsuka Pharmaceutical Co., Ltd. Key Developments
Otsuka Pharmaceutical Co., Ltd.’s JINARC Treatment Approves in Europe for Adults Living with ADPKD
May 27 15
Otsuka Pharmaceutical Co., Ltd. announced that the European Commission has granted marketing authorization for JINARC for the treatment of ADPKD in adults who have chronic kidney disease stage one to three at initiation of treatment with evidence of rapidly progressing disease. In receiving this marketing authorisation, tolvaptan becomes the first pharmaceutical therapy to be licensed in Europe for the treatment of the underlying pathophysiology of ADPKD. The marketing authorisation for tolvaptan is based on the findings of the pivotal Phase III randomised, double-blind and placebo-controlled TEMPO 3:4 trial the large clinical study conducted in ADPKD to date.1 In the three-year study, the rate of TKV increase over 3 years was significantly less for tolvaptan-treated subjects than for subjects receiving placebo: 2.80% per year vs 5.51% per year, respectively in ADPKD. Tolvaptan is a potent vasopressin V2 receptor antagonist that has been proven to slow cyst growth and renal function decline in patients with ADPKD in CKD stage one to three with evidence of rapidly progressive disease. The formation of cysts associated with ADPKD can lead to significant kidney damage, even when kidney function is not affected10 and cause complications that include chronic and acute pain, hypertension and kidney failure. In addition to the physical symptoms, ADPKD causes a profound psychological and emotional burden for those living with the disease, their families and loved ones. By selectively blocking vasopressin from its V2 receptor, tolvaptan decreases cyst cell proliferation and fluid secretion, ultimately reducing cyst development and renal clinical events associated with disease progression.
Takeda Pharmaceutical Company Limited and Otsuka Pharmaceutical Co., Ltd. Enter into Agreement for Co-Promotion of TAKECAB
Mar 26 15
Takeda Pharmaceutical Company Limited and Otsuka Pharmaceutical Co., Ltd. announced that Takeda submitted a new drug application to the Ministry of Health, Labour and Welfare for a single pack containing drugs which is the eradication of the Helicobacter Pylori. These drugs are available in the form of a single pack. One pack contains three drugs for the first eradication of H. pylori, namely, TAKECAB® (generic name: Vonoprazan fumarate, hereinafter “TAKECAB”) — developed by Takeda for treating acid-related diseases through a novel mechanism of action using potassium-competitive acid blockers (P-CABs) — amoxicillin (Japanese brand name: AMOLIN®), and clarithromycin (Japanese brand name: Clarith®). Another contains three drugs for the second eradication of H. pylori, namely, TAKECAB, amoxicillin, and metronidazole (Japanese brand name: Flagyl®). Takeda and Otsuka executed an agreement at the end of March 2014 to co-promote TAKECAB® (for treating acid-related diseases) in Japan. Under the agreement, the two companies will conduct informational activities about a single pack for the eradication of Helicobacter pylori for healthcare professionals after approval of it and address unmet clinical needs in the treatment of acid-related diseases. Otsuka will receive co-promotion fees from Takeda based on sales of TAKECAB® and the single pack containing TAKECAB® (in accordance with conditions specified in the agreement).
Takeda Pharmaceutical Company Limited and Otsuka Pharmaceutical Company, Limited Unveil Takecab in Japan
Mar 10 15
Takeda Pharmaceutical Company Limited and Otsuka Pharmaceutical Company, Limited have announced the availability of Takecab 10mg and Takecab 20mg, or Vonoprazan fumarate, in Japan. TAKECAB, discovered by Takeda, is a new medicine for treating acid-related diseases with a novel mechanism of action called potassium-competitive acid blockers (P-CABs) which competitively inhibits the binding of potassium ions to H+,K+-ATPase (also known as the proton pump) in the final step of gastric acid secretion in gastric parietal cells. Vonoprazan fumarate has fast-acting, strong and sustained acid secretion inhibitory effects. Takeda and Otsuka executed an agreement at the end of March 2014 to co-promote TAKECAB in Japan.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|